The use of rh-NGF in the management of neurotrophic keratopathy

Neurotrophic keratitis or keratopathy (NK) is a degenerative corneal disease induced by impairment of the trigeminal nerve function. This condition may lead to persistent epithelial defects, corneal ulceration, and perforation. The diagnosis of NK requires a careful investigation of any ocular and s...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in ophthalmology Vol. 4; p. 1408587
Main Authors Roszkowska, Anna M, Spinella, Rosaria, Calderone, Alessandro, Sindoni, Marianna, Wowra, Bogumił H, Kozak, Maciej, Sajak-Hydzik, Katarzyna, Aliò, Jorge
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 08.07.2024
Subjects
cenegermin
corneal sensitivity
nerve growth factors
neurotrophic keratitis
Ophthalmology
persistent epithelial defects
rh-NGF
persistent epithelial defects
rh-NGF
cenegermin
nerve growth factors
corneal sensitivity
neurotrophic keratitis
Online AccessGet full text

Cover

More Information
Summary:Neurotrophic keratitis or keratopathy (NK) is a degenerative corneal disease induced by impairment of the trigeminal nerve function. This condition may lead to persistent epithelial defects, corneal ulceration, and perforation. The diagnosis of NK requires a careful investigation of any ocular and systemic condition associated with the disease and ocular surface and corneal sensitivity examinations. In the past, several medical and surgical procedures were used to treat this condition with different clinical effectiveness. Cenegermin is a recombinant human nerve growth factor (rh-NGF) that supports corneal reinnervation. Different clinical trials have demonstrated the safety and efficacy of topical cenegermin in patients with moderate to severe neurotrophic keratitis. In this review, we report the literature on clinical results regarding the treatment of NK with cenegermin since its approval by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) in 2017 and 2018, respectively.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Edited by: Sudi Patel, Svjetlost Clinic, Croatia
Ioannis Aslanides, Emmetropia Mediterranean Eye Institute, Greece
Reviewed by: Davide Borroni, Riga Stradiņš University, Latvia
ISSN:2674-0826
2674-0826
DOI:10.3389/fopht.2024.1408587